July 1 Company Quick Takes: Alnylam submits MAA for hepatic porphyria therapy; plus Sage, Amicus and PTC
Alnylam submits hepatic porphyria therapy MAA
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) submitted an MAA to EMA for givosiran to treat acute hepatic porphyria. Last month, the biotech completed a rolling NDA for the subcutaneous RNAi therapeutic targeting ALAS-1 in the indication.
Sage launches postpartum therapy
Sage Therapeutics Inc. (NASDAQ:SAGE) has launched its postpartum depression therapy Zulresso brexanolone, according to partner Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Sage priced the drug at $34,000 (see "Sage Broadens the Spotlight on Postpartum Depression")...